Arcutis Biotherapeutics, Inc. ARQT Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s total liabilities & equity?
- Arcutis Biotherapeutics, Inc. (ARQT) reported total liabilities & equity of $460M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s total liabilities & equity changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s total liabilities & equity increased by 33.7% year-over-year, from $344.11M to $460M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s total liabilities & equity has grown at a 7.7% compound annual growth rate (CAGR), from $298.27M to $432.97M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.